This week, we have an in-depth conversation on molecular glue degradation, with Monte Rosa Therapeutics’ chief data and information officer John Castle.

Interview time:

03:52 Monte Rosa Therapeutics

Molecular glue degradation

A recent cover article in Science showcased research that expands by more than 1,000 the number of therapeutic targets (including undruggables) accessible through a protein degradation approach known as molecular glue degradation.

Using proprietary AI and ML approaches, researchers from Monte Rosa Therapeutics used algorithms to identify more than 1,600 human proteins predicted to be compatible with cereblon (a protein with a central role in cellular prot ...